Multiple Sclerosis

Krystyn Van Vliet, PhD, of Cornell University, discusses the scalability of 3D platforms in multiple sclerosis (MS) drug discovery and compares their costs with those of other drug discovery methods.

Patrick Vermersch, MD, PhD, University of Lille, France details the adverse events observed in the frexalimab trials and the next steps necessary to establish frexalimab as a standard of care in multiple sclerosis (MS) in the third and final part of an interview.

Results from this cohort study found that levels of glial fibrillary acid protein, cerebral spinal fluid, and neurofilament heavy chain are distinguishable biomarkers that are associated with disease outcomes in multiple sclerosis (MS).

Krystyn Van Vliet, PhD, vice president for research and innovation at Cornell University's Meinig School of Biomedical Engineering, discusses using engineered 3D platforms to identify potential multiple sclerosis (MS) drug candidates.

The FDA has declined to approve glatiramer acetate (GA) depot in the treatment of relapsing types of multiple sclerosis (MS), issuing a complete response letter (CRL) for the long-acting, injectable form of GA.

Patrick Vermersch, MD, PhD, University of Lille, France discusses the next steps in frexalimab trials and the findings that have surprised him the most thus far, the second part of an interview.

While the results of evolutionRMS, comparing evobrutinib with teriflunomide, were negative, that "doesn't mean that evobrutinib is not working," said Xavier Montalban, MD, PhD, director of the Multiple Sclerosis Center of Catalonia (Cemcat).

Ateyeh Soroush, a PhD candidate at the University of Calgary, explains her ongoing study utilizing near-infrared spectroscopy (NIRS) to investigate hypoxia-related brain function impairment in patients with multiple sclerosis (MS).

Patrick Vermersch, MD, PhD, joined The American Journal of Managed Care® for an interview on promising data from a phase 2 clinical trial on frexalimab in the treatment of multiple sclerosis (MS) and associated neurodegeneration.

A meta-analysis of 3 case-controlled MS studies showed an association between susceptibility to multiple sclerosis (MS) and the vitamin D pathway.

A national single-center observational retrospective study reveals the long-term benefits of hematopoietic stem cell transplantation in the treatment of multiple sclerosis (MS).

A longitudinal, observational study found that the choroid plexus, a network of blood vessels in each ventricle of the brain, plays a potential role in the neurodegenerative and chronic inflammatory process experienced by patients with relapsing remitting multiple sclerosis (MS).

The use of ibudilast in the treatment of progressive multiple sclerosis (MS) has been suggested to reduce lesion volume in patients.

A large-scale, population-based study examined patterns of disease-modifying therapy (DMT) exposure in pregnant patients with MS since 2010, revealing increased occurrences and the need for future studies to examine the impact of newer-developed DMTs.

A community-based study suggests a correlation between university education and the likelihood of disease-modifying therapy (DMT) uptake in multiple sclerosis (MS).

A cross-sectional analysis evaluated a myriad of socioeconomic and demographic factors that drive stigma experienced by patients with multiple sclerosis (MS).

Exposure to tobacco smoke in utero has the potential to make offspring more vulnerable to developing multiple sclerosis (MS).

More research is necessary to understand cerebral oxygen consumption as a predictive biomarker for brain atrophy in multiple sclerosis (MS); however, this study found that mitochondrial dysfunction could have a role in the underlying pathophysiology of MS.

A prospective analysis suggested that those with pediatric-onset multiple sclerosis (MS) who experienced earlier disease-modifying treatment initiation may be less vulnerable to disease progression.

A population-based study drew a possible connection between gastrointestinal (GI) symptoms and the multiple sclerosis (MS) prodrome.

Misdiagnoses of multiple sclerosis (MS) represent one of the prominent challenges in MS for patients, clinicians, and researchers. A variety of factors influence misdiagnosis, including testing deficiencies, copycat diseases, and more.

A single-center, observational study conducted in the Czech Republic investigated the determining factors in delayed diagnoses in multiple sclerosis (MS) and how these delays impact patient outcomes.

A recent meta-analysis revealed significant differences in characteristic between patients with neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS), highlighting the need for enhanced tools to differentiate between these diseases for early and accurate diagnosis.

This year’s most-read articles on multiple sclerosis (MS) explored the emergence of new medications, modes of therapy, and predictive tools in the study of MS.

Results showed that evobrutinib did not produce a more superior reduction in annualized relapse rates than teriflunomide, a previously approved disease-modifying agent.